CDK4 and neoplasm: These studies highlight the mechanistic basis for combining CDK4/6 inhibitors and PD-1/PD-L1 inhibitors as this combinatorial approach stimulates an immunogenic tumor microenvironment and primes cancers for PD1/PD-L1 immune checkpoint blockade.